M K Brawer

1.5k total citations
36 papers, 1.1k citations indexed

About

M K Brawer is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Rheumatology. According to data from OpenAlex, M K Brawer has authored 36 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Pulmonary and Respiratory Medicine, 9 papers in Surgery and 8 papers in Rheumatology. Recurrent topics in M K Brawer's work include Prostate Cancer Diagnosis and Treatment (22 papers), Prostate Cancer Treatment and Research (18 papers) and Urologic and reproductive health conditions (7 papers). M K Brawer is often cited by papers focused on Prostate Cancer Diagnosis and Treatment (22 papers), Prostate Cancer Treatment and Research (18 papers) and Urologic and reproductive health conditions (7 papers). M K Brawer collaborates with scholars based in United States, United Kingdom and Australia. M K Brawer's co-authors include P.H. Lange, J. L. Stanford, Barbara McKnight, Virginia A. Clark, John M. Kittelson, Raymond B. Nagle, Janet R. Daling, Kristine G. Wicklund, Frederick R. Ahmann and Ron B. Schifman and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and American Journal of Epidemiology.

In The Last Decade

M K Brawer

35 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
M K Brawer United States 21 811 245 226 168 155 36 1.1k
Gustavo de la Roza United States 15 705 0.9× 249 1.0× 261 1.2× 232 1.4× 104 0.7× 39 1.1k
Thomas Seay United States 14 862 1.1× 298 1.2× 101 0.4× 298 1.8× 181 1.2× 28 1.1k
Annika Herlemann Germany 18 785 1.0× 214 0.9× 108 0.5× 149 0.9× 249 1.6× 75 1.1k
Frédéric Staerman France 16 913 1.1× 272 1.1× 82 0.4× 327 1.9× 153 1.0× 45 1.2k
Peter Hammerer Germany 15 478 0.6× 111 0.5× 190 0.8× 155 0.9× 140 0.9× 52 868
Michael Aitchison United Kingdom 19 444 0.5× 181 0.7× 395 1.7× 293 1.7× 49 0.3× 45 866
Kenneth R. Blank United States 10 669 0.8× 137 0.6× 155 0.7× 200 1.2× 39 0.3× 18 967
Wolfgang Lilleby Norway 20 750 0.9× 67 0.3× 246 1.1× 135 0.8× 46 0.3× 77 1.2k
Rachel E. Carlson United States 15 610 0.8× 155 0.6× 138 0.6× 96 0.6× 37 0.2× 41 751
Jacques Planas Spain 22 1.2k 1.5× 222 0.9× 330 1.5× 165 1.0× 140 0.9× 137 1.6k

Countries citing papers authored by M K Brawer

Since Specialization
Citations

This map shows the geographic impact of M K Brawer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M K Brawer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M K Brawer more than expected).

Fields of papers citing papers by M K Brawer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M K Brawer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M K Brawer. The network helps show where M K Brawer may publish in the future.

Co-authorship network of co-authors of M K Brawer

This figure shows the co-authorship network connecting the top 25 collaborators of M K Brawer. A scholar is included among the top collaborators of M K Brawer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M K Brawer. M K Brawer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Cuzick, Jack, Steven Stone, Gabrielle Fisher, et al.. (2015). Validation of an RNA cell cycle progression score for predicting death from prostate cancer in a conservatively managed needle biopsy cohort. British Journal of Cancer. 113(3). 382–389. 109 indexed citations
2.
Bartsch, Georg, M K Brawer, Carol D Cheli, et al.. (2003). Predicting cancer on repeat biopsy: Results of a multicenter prospective evaluation of complexed PSA. European Urology Supplements. 2(1). 183–183. 2 indexed citations
3.
Brawer, M K, et al.. (2000). Polyamine depletion therapy in prostate cancer. Prostate Cancer and Prostatic Diseases. 3(4). 275–279. 36 indexed citations
4.
Murphy, G.P., et al.. (2000). Evaluation of prostate cancer patients receiving multiple staging tests, including ProstaScint� scintiscans. The Prostate. 42(2). 145–149. 22 indexed citations
5.
Brawer, M K, et al.. (1998). Prospective evaluation of percent free-PSA and complexed-PSA for early detection of prostate cancer. Prostate Cancer and Prostatic Diseases. 1(4). 197–203. 54 indexed citations
6.
Nixon, Randy G. & M K Brawer. (1997). Enhancing the specificity of prostate‐specific antigen (PSA): an overview of PSA density, velocity and age‐specific reference ranges. British Journal of Urology. 79(S1). 61–67. 32 indexed citations
7.
MEYER, GRANT E., et al.. (1997). Histologic differences in benign prostate hyperplasia between Chinese and American men. The Prostate. 31(3). 175–179. 11 indexed citations
8.
Zhu, Kathy Q., J. L. Stanford, J R Daling, et al.. (1996). Vasectomy and Prostate Cancer: A Case-Control Study in a Health Maintenance Organization. American Journal of Epidemiology. 144(8). 717–722. 50 indexed citations
9.
Nelson, Peter S., et al.. (1996). Chemoprevention for ProstaticIntraepithelial Neoplasia. European Urology. 30(2). 269–278. 14 indexed citations
10.
11.
García-Jiménez, Rocío, et al.. (1996). Prostatic intraepithelial neoplasia: significance and management.. PubMed. 14(3). 149–55. 11 indexed citations
12.
Brawer, M K. (1995). How to use prostate-specific antigen in the early detection or screening for prostatic carcinoma. CA A Cancer Journal for Clinicians. 45(3). 148–164. 26 indexed citations
13.
Wener, Mark H., et al.. (1995). Variation in measurement of prostate-specific antigen: importance of method and lot variability.. PubMed. 41(12 Pt 1). 1730–7. 24 indexed citations
14.
Brawer, M K. (1994). Staging for prostate cancer. JAMA. 271(20). 1628a–1629. 3 indexed citations
15.
Brawer, M K, et al.. (1993). Prostatic intraepithelial neoplasia and prostate-specific antigen. World Journal of Urology. 11(4). 196–200. 33 indexed citations
16.
Brawer, M K. (1993). Terazosin in the treatment of benign prostatic hyperplasia. Terazosin Benign Prostatic Hyperplasia Study Group. Archives of Family Medicine. 2(9). 929–935. 61 indexed citations
17.
Τakayama, Thomas K. & M K Brawer. (1992). Prostate ultrasonography in normal and benign conditions. World Journal of Urology. 10(4). 1 indexed citations
18.
Brawer, M K. (1991). Prostate Specific Antigen: A review. Acta Oncologica. 30(2). 161–168. 22 indexed citations
19.
Brawer, M K & P.H. Lange. (1989). Prostate-Specific Antigen and Premalignant Change: Implications for Early Detection. CA A Cancer Journal for Clinicians. 39(6). 361–375. 37 indexed citations
20.
Brawer, M K, et al.. (1988). The effect of digital rectal examination on serum levels of prostatic-specific antigen.. PubMed. 112(11). 1110–2. 59 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026